Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sotera Health (SHC) EBITDA Margin (2020 - 2026)

Sotera Health has reported EBITDA Margin over the past 6 years, most recently at 16.65% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4122.0% year-over-year to 16.65%; the TTM value through Dec 2025 reached 15.16%, up 2162.0%, while the annual FY2025 figure was 15.16%, 2162.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 16.65% at Sotera Health, up from 10.02% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 30.28% in Q2 2025 and troughed at 104.29% in Q4 2022.
  • A 5-year average of 0.35% and a median of 2.86% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: surged 15715bps in 2021 and later tumbled -12826bps in 2022.
  • Year by year, EBITDA Margin stood at 23.98% in 2021, then tumbled by -535bps to 104.29% in 2022, then skyrocketed by 119bps to 19.38% in 2023, then crashed by -227bps to 24.57% in 2024, then surged by 168bps to 16.65% in 2025.
  • Business Quant data shows EBITDA Margin for SHC at 16.65% in Q4 2025, 10.02% in Q3 2025, and 30.28% in Q2 2025.